Related Experiment Video
Updated: Apr 15, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Novel CD9-targeted therapies in gastric cancer
Yoko Murayama1, Kenji Oritani1, Shusaku Tsutsui1
1Yoko Murayama, Shusaku Tsutsui, Department of Gastroenterology and Hepatology, Itami City Hospital, Itami 664-8540, Japan.
Abstract:
There are 33 human tetraspanin proteins, emerging as key players in malignancy, the immune system, fertilization, cellular signaling, adhesion, morphology, motility, proliferation, and tumor invasion. CD9, a member of the tetraspanin family, associates with and influences a variety of cell-surface molecules. Through these interactions, CD9 modifies multiple cellular events, including adhesion, migration, proliferation, and survival. CD9 is therefore considered to play a role in several stages during cancer development. Reduced CD9 expression is generally related to venous vessel invasion and metastasis as well as poor prognosis. We found that treatment of mice bearing human gastric cancer cells with anti-CD9 antibody successfully inhibited tumor progression via antiproliferative, proapoptotic, and antiangiogenic effects, strongly indicating that CD9 is a possible therapeutic target in patients with gastric cancer. Here, we describe the possibility of CD9 manipulation as a novel therapeutic strategy in gastric cancer, which still shows poor prognosis.
Insights
Targeting CD9, a protein involved in cell functions, shows promise for treating gastric cancer. Inhibiting CD9 in mice reduced tumor growth, suggesting it as a potential therapeutic target for this disease.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Tetraspanin proteins, including CD9, are crucial in various cellular processes like adhesion, motility, and proliferation.
- CD9 influences multiple cell-surface molecules, impacting cancer development, invasion, and metastasis.
- Reduced CD9 expression correlates with poor prognosis and increased metastasis in gastric cancer.
Purpose of the Study:
- To investigate the therapeutic potential of targeting CD9 in gastric cancer.
- To evaluate the effects of anti-CD9 antibody treatment on gastric tumor progression in a preclinical model.
Main Methods:
- Treatment of mice bearing human gastric cancer xenografts with an anti-CD9 antibody.
- Assessment of tumor progression, including antiproliferative, proapoptotic, and antiangiogenic effects.
Main Results:
- Anti-CD9 antibody treatment significantly inhibited gastric tumor progression in mice.
- The inhibition was mediated by antiproliferative, proapoptotic, and antiangiogenic mechanisms.
- These findings highlight CD9's role in gastric cancer development and progression.
Conclusions:
- CD9 is a potential therapeutic target for gastric cancer.
- Manipulation of CD9 offers a novel therapeutic strategy for improving outcomes in patients with gastric cancer, a disease with a currently poor prognosis.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:34Inhibition of Cdk Activity
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...